Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting by Obirikorang, Christian & Yeboah, Francis A
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Journal of Biomedical Science
Open Access Research
Blood haemoglobin measurement as a predictive indicator for the 
progression of HIV/AIDS in resource-limited setting
Christian Obirikorang*1,2 and Francis A Yeboah1
Address: 1Department of Molecular Medicine, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and 
Technology (KNUST), Kumasi, Ghana and 2University Hospital, Laboratory Department, KNUST, Kumasi, Ghana
Email: Christian Obirikorang* - krisobiri@yahoo.com; Francis A Yeboah - fayeboah@yahoo.co.uk
* Corresponding author    
Abstract
Background: Anaemia is a frequent complication of infection with the human immunodeficiency
virus (HIV) and may have multiple causes. The objective of this study was to find out if blood
haemoglobin measurement could be used as an indicator for the progression of HIV/AIDS in
resource-limited setting.
Methods:  Two hundred and twenty-eight (228) consented People Living with HIV/AIDS
(PLWHAs) who were placed in three groups according to their CD4 counts were used in the
study. The three groups were those with CD4 counts (1) ≥ 500 mm-3; (2) 200-499 mm-3; and (3)
<200 mm-3. One hundred (100) sex, age-matched and healthy HIV-seronegative individuals were
used as control subjects. Blood haemoglobin, blood haematocrit, Red cell indices which included
Mean Cell Volume, Mean Cell Haemoglobin Concentration and Mean Cell Haemoglobin and CD4
count were analysed in all subjects.
Results: The mean blood haemoglobin concentrations in those with CD4 counts <200 mm-3, 200-
499 mm-3 and ≥ 500 mm-3 (8.83 ± 0.22 g/dl, 10.03 ± 0.31 g/dl and 11.3 ± 0.44 g/dl respectively)
were significantly lower when compared with the control group (14.29 ± 0.77 g/dl) (p < 0.0001).
The mean blood haematocrit levels in those with CD4 counts <200 mm-3, 200-499 mm-3 and ≥
500 mm-3 (23.53 ± 0.85%, 28.28 ± 0.77% and 33.54 ± 1.35% respectively) were also significantly
lower when compared with the control group (41.15 ± 2.15%) (p < 0.0001). The red cell indices
were also lower in the subjects when compared with the control group. Using the Pearson's
correlation, there was a significant and positive correlation between the blood haemoglobin level
and their CD4 counts (r2 = 0.1755; p < 0.0001).
Conclusion: Anaemia in People Living with HIV/AIDS, if persistent, is associated with substantially
decreased survival. From our analysis, there was a decrease in the blood haemoglobin, levels as the
HIV infection progressed and our findings are consistent with those of other studies of anaemia as
a prognostic factor in HIV infection. Haemoglobin levels could be measured easily where resources
for more sophisticated laboratory markers such as viral load or even CD4 lymphocyte count are
not available given that measurement of the CD4 lymphocyte count requires flow cytometry, an
expensive technique unavailable in many developing countries. Regular measurements could help
to determine which patients are at greatest risk of disease progression, allowing these patients to
be identified for closer monitoring or therapeutic intervention.
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Background
HIV infection is the chief cause of morbidity and mortality
among adults and children, especially in sub-Saharan
Africa. At the end of 2007, 40 million persons worldwide
were living with HIV or AIDS [1]. Anaemia is a frequent
complication that occurs in 20-80% of HIV-infected per-
sons and is associated with faster disease progression and
mortality [2]. This makes it more common than thrombo-
cytopenia or leucopenia in patients with AIDS [3]. There-
fore, interventions to prevent anaemia may lead to
improved health and survival potential of HIV-infected
persons [4].
HIV infection may lead to anemia in many ways: changes
in cytokine production with subsequent effects on hemat-
opoiesis [5,6] decreased erythropoietin concentrations [7]
opportunistic infectious agents, such as Mycobacterium
avium complex [8] and parvovirus B- [9] administration of
chemotherapeutic agents such as zidovudine, ganciclovir,
[10] and trimethoprimsulfamethoxazole [11] and myelo-
phthisis caused by cancers such as lymphosarcoma. Other
mechanisms for HIV-associated anaemia, although
uncommon, include vitamin B12 deficiency [12] and the
autoimmune destruction of red blood cells[13]. Anaemia
has been associated with progression to AIDS and shorter
survival times[14] for HIV-infected patients.
While CD4 count and HIV-RNA are the gold standard
markers for disease monitoring in PLWHAs, when meas-
urement of these parameters is not possible surrogate
markers become important. Markers investigated for their
utility as simple markers for disease progression in
resource-limited settings include delayed type hypersensi-
tivity responses (DTH), total lymphocyte count (TLC),
haemoglobin and body mass index (BMI) [15].
Haemoglobin levels reflect rapidity of disease progression
rates and independently predict prognosis across demo-
graphically diverse cohorts [16,17]. Rates of haemoglobin
decrease also correlate with falling CD4 counts [18,19].
There have been suggestions that increases in haemo-
globin are predictive of treatment success [20]. While
racial variation in normal haemoglobin ranges and the
side effects of antiretroviral agents such as zidovudine on
the HIV infected bone marrow must be taken into account
[21], monitoring haemoglobin levels shows utility in pre-
dicting disease progression both before and following
HAART initiation.
The aim of this study was, therefore, to determine if blood
haemoglobin measurement could be used as an indicator
for the progression of HIV/AIDS in limited resource-lim-
ited settings. We sought to compare the change in haemo-
globin levels in the patients as the disease progressed to a
Control group who were one hundred (100) sex- and age-
matched healthy, HIV-seronegative individuals. In addi-
tion, we sought to investigate the relationship between
haemoglobin and CD4 lymphocyte count in the HIV indi-
viduals.
Methods
This study was a prospective case control comparative
study which was conducted at one of the established cent-
ers providing Anti Retroviral Therapy (ART) and is located
at Cape Coast, the capital of the Central region of Ghana.
The study was conducted between August 2007 and May
2008. Blood samples were taken from the subjects before
the initiation of ART. This study was approved by the
Committee on Human Research, Publications and Ethics
(CHRPE), School of Medical Sciences, Kwame Nkrumah
University of Science & Technology (KNUST), Kumasi. All
patients enrolling in the study completed a written
informed consent form in accordance with the Helsinki
Declaration. After obtaining consent, demographic ques-
tionnaires were completed. Blood was drawn for CD4 cell
count, blood haemoglobin, blood haematocrit and Red
cell indices. The normal reference range for blood haemo-
globin was 12.0-18.0 g/dl and that of blood haematocrit
was 37-55%. The definition of anaemia chosen for this
study was therefore blood haemoglobin less than 12 g/dl
and blood haematocrit less than 37%. We chose this cut-
off for defining anaemia to exclude hereditary causes for
mild anaemia, such as thalassemia trait, and to allow for
use of a single cut-off that would clearly exclude normal
haemoglobin concentrations for both men and women.
In all one hundred and fifty (150) confirmed People Liv-
ing with HIV/AIDS (PLWHAs) were included in the study.
PLWHAs were placed in three (3) groups according to the
Centers for Disease Control and Prevention Criteria
(CDC) classification system that emphasizes the impor-
tance of CD4+ T lymphocyte testing in clinical manage-
ment of HIV-infected persons. The system is based on
three ranges of CD4 counts (1) ≥ 500 mm-3; (2) 200-499
mm-3; and (3) <200 mm-3 . Control subjects were one
hundred (100) sex- and age-matched healthy (39.4 ± 13.4
years), HIV-seronegative individuals.
The blood haemoglobin, blood haematocrit and Red cell
indices were determined by automated blood analyzer
(CELL-DYN 1800, Abbott Laboratories Diagnostics Divi-
sion, USA). A modified Methemoglobin method was used
for the colorimetric determination of hemoglobin. A por-
tion of the lysed, diluted sample from the WBC Mixing
Chamber was used for HGB measurement. A low-energy
Light-Emitting Diode (LED) was used as the light source.
The LED shone through the HGB flow cell and a 540 nm
narrow-bandwidth filter onto a photo detector. The HGB
concentration was directly proportional to the absorbency
of the sample.Journal of Biomedical Science 2009, 16:102 http://www.jbiomedsci.com/content/16/1/102
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The CD4 T lymphocytes count was determined using the
Becton Dickinson (BD) FASCount system (Becton, Dick-
inson and Company, Califonia, USA). The BD FASCount
system used flow cytometry for the quantification of the
CD4 T Lymphocytes. Flow cytometry uses the principles
of light scattering, light excitation, and emission of fluor-
ochrome molecules to generate specific multi-parameter
data from particles and cells in the size range of 0.5 um to
40 um diameter. Flow cytometry is the recognized gold
standard for CD4 testing, and is used to stage HIV/AIDS,
guide treatment decisions for HIV-infected persons, and
evaluate effectiveness of therapy.
Statistical Analysis
The OUTLIERS preliminary test for detection of error val-
ues was initially applied for statistical analysis. The results
were given as mean ± Standard error of mean (SEM). Cor-
relations were evaluated using the Pearson's correlation
test. For all statistical comparisons, the level of signifi-
cance was set at p < 0.05. All data analysis in this research
was done using GraphPad Prism for Windows version
4.02 (GraphPad Software, San Diego, CA, USA).
Results
Demographic characteristics of patients used in this study
are shown below in table 1. There were no significant dif-
ference between the ages of the test subjects and the con-
trol. There were however significant differences in the
CD4 count between the control group and those with
CD4 count <200 (p < 0.0001) and 200-499 (p < 0.0001).
The mean blood haemoglobin level of the test subjects
were 11.3 ± 0.44 g/dl, 10.03 ± 0.31 g/dl and 8.83 ± 0.22
g/dl for CD4 ≥ 500 mm-3, 200-499 mm-3 and ≤ 200 mm-3
respectively and that of the control group was 14.29 ±
0.77 g/dl as shown in figure 1A. The mean blood haema-
tocrit level of the test subjects were 33.54 ± 1.35%, 28.28
± 0.77% and 23.53 ± 0.85% for CD4 ≥ 500 mm-3, 200-
499 mm-3 and ≤ 200 mm-3 respectively and that of the
control group was41.15 ± 2.15% as shown in figure 1B.
Blood haemoglobin and haematocrit levels decreased
suggesting increased risk of developing anaemia as the
HIV infection progressed. At a cut-off of 12.0 g/dl, 82.40%
of the test subjects were found to be anaemic with 4.1% of
the control group also being anaemic.
One-way ANOVA revealed a significant difference
between the test subjects and the control group (F3, 228 =
13.24; p < 0.0001). A further post-test analysis using the
Bonferroni's Multiple Comparison Test revealed that
there was a significant difference between the control
group and the subjects with CD4 count <200 and CD4
count between 200 and 499 (p < 0.0001). There was how-
ever no significant difference between the control group
and those with CD4 count greater than 500 (p = 0.13).
There was also a significant different between the subjects
with CD4 count greater than 500 and those with CD4
count less than 200 (p < 0.001).
Using the Pearson's correlation, there was a significant
and positive correlation (r2 = 0.1755; p < 0.0001) between
the blood haemoglobin level and their respective CD4
counts as shown in figure 2A. Thus as the blood CD4
count of the subjects decreased there was a decrease in
their respective blood haemoglobin levels. Blood haema-
tocrit also had a similar trend as the blood haemoglobin.
A correlation analysis between the CD4 count of the test
subjects and their respective haematocrit levels revealed a
significant and positive correlation (r2  = 0.1869; p  <
0.0001) as shown in figure 2B.
The mean values for MCV, MCH and MCHC are shown in
figure 3. There were significant difference between the
MCV of the control group and those with CD4<200 (p <
0.001) and 200-499 (p < 0.05). There were however no
significant difference between the MCH of the control
group and the various groups of the test subjects.
Discussion
The incidence of anemia was strongly and consistently
associated with the progression of HIV disease as meas-
ured by CD4 count (figure 3). This association is most
Table 1: Demographic characteristic of the Subjects and Controls. 
Parameter Control Total Subjects CD4>500 CD4 200-500 CD4<200
Age, (years) 38.76 ± 1.73 37.10 ± 0.84 38.72 ± 2.58 37.43 ± 1.57 36.68 ± 1.08
Males, (n) 72 157 22 47 88
Females, (n) 28 71 21 16 34
CD4 count, (mm-3) 1045.45 ± 77.53 226.0+21.17*** 823.1 ± 60.75 310.70 ± 14.44*** 84.30 ± 77.53***
HIV serotype 1, (n) - 138 22 34 82
HIV serotype 2, (n) - 1 - - 1
HIV serotype 1 and 2,(n) - 89 20 27 42
The values are expressed as mean ± SEMJournal of Biomedical Science 2009, 16:102 http://www.jbiomedsci.com/content/16/1/102
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likely explained by the increasing viral burden as HIV dis-
ease progresses, which could cause anemia by increased
cytokine mediated myelosuppression. Alternatively, ane-
mia may be a surrogate marker for some aspect of disease
progression not captured by controlling for CD4 count
and clinical AIDS diagnosis. Our study results are consist-
ent with previous studies which showed that low haemo-
globin levels increase the risk of AIDS [22,23] increase the
risk of death in patients with AIDS [24-26] and increase
the risk of death among patients with advanced immuno-
deficiency[27,28], both in cross-sectional [29] and longi-
tudinal studies [22]. Several staging systems have
suggested that important information can be provided by
haemoglobin levels [27,28,30]. Significant and positive
correlation was found when blood haemoglobin level was
compared with their respective CD4 count (Figure 2) of
CDC staging of CD4 counts on (A) Blood haemoglobin and  (B) Blood haematocrit in HIV patients and control group Figure 1
CDC staging of CD4 counts on (A) Blood haemo-
globin and (B) Blood haematocrit in HIV patients and 
control group. The results are presented as means ± SEM. 
***P ≤ 0.0001, compared to respective control (one way 
ANOVA followed by Bonferroni's post hoc). (Hb: haemo-
globin, HCT: haematocrit, CDC: Centre for Disease Con-
trol).
Linear correlation between CD4 count and blood (A) Hae- moglobin and (B) Haematocrit, in patients with HIV infection Figure 2
Linear correlation between CD4 count and blood (A) 
Haemoglobin and (B) Haematocrit, in patients with 
HIV infection. (r = correlation coefficient).Journal of Biomedical Science 2009, 16:102 http://www.jbiomedsci.com/content/16/1/102
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the subject group. Our results also show that haemo-
globin levels provide prognostic information independ-
ent of that provided by the CD4 lymphocyte count.
Although the cut-offs we used to define anaemia differ
from those in a paper by [31], this results agree well with
this recent study, which used the latest measure of haemo-
globin and CD4 lymphocyte count in a similar way to our
analysis [32]. From the Red cell indices analysis, most of
the test subjects had low MCV and MCHC as compared to
the control group. Our findings are consistent with those
of [33] who found that the majority of test subjects pre-
sented with microcytic hypochromic anaemia which is
common in most chronic diseases (figure 3).
Most of our data was collected before common use of the
new highly active antiretroviral therapies. Before the
introduction of HAART, investigators reported that the
annual loss of CD4 lymphocyte counts was 40-80 × 106
cells/l [34-37]. Measurement of the loss of haemoglobin
during HIV infection has not previously been reported. It
was interesting to note that the change in haemoglobin in
our study was gradual and a continual process. There have
been considerable changes in the availability of antiretro-
viral regimens and in the way they are combined in the
EuroSIDA study [38]. The pathogenesis of HIV-associated
anaemia is unclear and is likely to be multifactorial in
nature [39,40]. Possible causes are bleeding (gastrointes-
tinal malignancy/severe infection), insufficient dietary
intake (vitamins such as cobalamin and folate, iron, and
general malnutrition), haemolytic anaemia (i.e. malig-
nancies, infections, splenomegaly, and immune dysfunc-
tion), and changes in erythropoietin synthesis and/or
bone marrow suppression. Suppression of the bone mar-
row in HIV-infected patients may be initiated in several
ways. These include an action of HIV itself (infection of
the progenitor of the red blood cell synthesis in late-stage
disease), direct pathogenic involvement of the bone mar-
row (malignant lymphoma, atypical mycobacteriosis),
prophylactic or therapeutic treatment against opportunis-
tic diseases or malignancies (i.e. sulphamethoxazole, gan-
ciclovir, methotrexate, adriamycin) or simply non-specific
effects relative to chronic or acute infections.
Haemoglobin is both easy and inexpensive to measure
and it was measured before the initiation of ART. Clearly
patients who developed severe anaemia before the initia-
tion of ART were at an increased risk of death. Monitoring
haemoglobin levels could be used to alert clinicians to
those patients who require more regular clinical follow-up
or who may need treatment for their anaemia. Moore et
al, (1998) found that treatment of anaemia with erythro-
poietin was associated with an improved prognosis possi-
bly by allowing higher doses or prolonged use of drugs
such as zidovudine and ganciclovir. In a recent cross-sec-
tional study, haemoglobin measurement was shown to
play an important role in the basic management of HIV
disease in West Africa [41].
In conclusion, given its strong relationship with AIDS-
defining illness and death, haemoglobin levels could be
CDC staging of CD4 counts on (A) MCV (B) MCHC and (C)  MCH in HIV patients and control group Figure 3
CDC staging of CD4 counts on (A) MCV (B) MCHC 
and (C) MCH in HIV patients and control group. The 
results are presented as means ± SEM. **P ≤ 0.001, *P ≤ 0.05 
compared to respective control (one way ANOVA followed 
by Bonferroni's post hoc). (MCV: Mean Cell Volume, MCH: 
Mean Cell Haemoglobin MCHC: Mean Cell Haemoglobin 
concentration, CDC: Centre for Disease Control).Journal of Biomedical Science 2009, 16:102 http://www.jbiomedsci.com/content/16/1/102
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measured easily in PLWHAs where resources for more
sophisticated laboratory markers such as viral load or
even CD4 lymphocyte count are not available (given that
measurement of the CD4 lymphocyte count requires flow
cytometry, an expensive technique unavailable in many
developing countries) [42]. Regular measurements of
blood haemoglobin in PLWHAs in resource-setting could
help to determine which HIV patients are at greatest risk
of disease progression, allowing these patients to be iden-
tified for closer monitoring or therapeutic intervention.
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